alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**EXHIBIT 31.1**
**CERTIFICATIONS**
I, James A. Watt, certify that:
     1. I have reviewed this quarterly report on Form 10-Q of RemingtonOil and Gas Corporation;
     2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessaryto make the statements made, in light of the circumstances under whichsuch statements were made, not misleading with respect to the periodcovered by this report;
     3. Based on my knowledge, the financial statements, and otherfinancial information included in this report, fairly present in allmaterial respects the financial condition, results of operations and cashflows of the registrant as of, and for, the periods presented in thisreport;
     4. The registrant’s other certifying officer(s) and I areresponsible for establishing and maintaining disclosure controls andprocedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) forthe registrant and have:
     (a) Designed such disclosure controls and procedures, or causedsuch disclosure controls and procedures to be designed under oursupervision, to ensure that material information relating to theregistrant, including its consolidated subsidiaries, is made known to usby others within those entities, particularly during the period in whichthis report is being prepared;
     (b) Evaluated the effectiveness of the registrant’s disclosurecontrols and procedures and presented in this report our conclusionsabout the effectiveness of the disclosure controls and procedures, as ofthe end of the period covered by this report based on such evaluation;and
     (c) Disclosed in this report any change in the registrant’sinternal control over financial reporting that occurred during theregistrant’s most recent fiscal quarter (the registrant’s fourth fiscalquarter in the case of an annual report) that has materially affected,or is reasonably likely to materially affect, the registrant’s internalcontrol over financial reporting; and
     5. The registrant’s other certifying officer(s) and I havedisclosed, based on our most recent evaluation of internal control overfinancial reporting, to the registrant’s auditors and the audit committeeof the registrant’s board of directors (or persons performing theequivalent functions):
     (a) All significant deficiencies and material weaknesses in thedesign or operation of internal control over financial reporting whichare reasonably likely to adversely affect the registrant’s ability torecord, process, summarize and report financial information; and
     (b) Any fraud, whether or not material, that involves managementor other employees who have a significant role in the registrant’sinternal control over financial reporting.
Date: July 28, 2004   /s/ James A. Watt James A. Watt*Chief Executive Officer*
##### 



EXHIBIT 99.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of SPARTA, Inc. (the
Company) for the period ended June 29, 2003, as filed with the Securities and
Exchange Commission on the date hereof (the Report), I, Robert C. Sepucha,
Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:



| | (1) |  | The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and                               
| | --- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------
|
| | (2) |  | The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of
the Company.

August 11, 2003

/s/ Robert C. Sepucha
Robert C. Sepucha
Chief Executive Officer
Docket No. FAA-2014-0531

 Contacts. With whom outside the FAA has this proposal been discussed? 

Organization Person Contacted Date Response 

National Business Aircraft Association Eli Cotti 7/10/14

Regional Airline Association 7/10/14

Aircraft Owners & Pilots Association Robert Hackman 7/10/14

Airlines for America Robert Ireland 7/10/14
Before the Third Division,

July 17, 1957

No. 61065.

protest 290458-K (New York).

#### Judson Sheldon Division, National Carloading Corporation *v.*United States,

Opinion by

Richardson, J.

In'accordance with rule 5 (b) of the rules of this court, as amended, the protest was dismissed for lack of prosecution.
```

[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 491 Engrossed in House (EH)]

                In the House of Representatives, U. S.,

                                                         June 18, 2007.
    Resolved,  That during the remainder of the 110th Congress it shall not be 
in order to consider a conference report to accompany a regular general 
appropriation bill unless the joint explanatory statement prepared by the 
managers on the part of the House and the managers on the part of the Senate 
includes a list of congressional earmarks (as that term is used in clause 9(d) 
of rule XXI) in the conference report or joint statement (and the name of any 
Member, Delegate, Resident Commissioner, or Senator who submitted a request to 
the respective House or Senate committee for each respective item included on 
such list) that were not committed to the conference committee by either House, 
not in a report on such bill, and not in a report of a committee of the Senate 
on a companion measure.
    Sec. 2.  It shall not be in order to consider a rule or order that waives 
the application of the first section of this resolution.
    Sec. 3.  A point of order under this resolution shall be disposed of by the 
question of consideration under the same terms as specified in clause 9(b) of 
rule XXI.
            Attest:

                                                                          Clerk.
```
<PAGE>   1

EXHIBIT 11

                                  SPARTA, INC.

                  EXHIBIT TO CONSOLIDATED FINANCIAL STATEMENTS
                  --------------------------------------------
                        COMPUTATION OF PER SHARE EARNINGS
                        ---------------------------------

<TABLE>
<CAPTION>
                           Three months ended June 30            Six months ended June 30
                          -----------------------------       -----------------------------
                             1998              1997              1998               1997
                          -----------       -----------       -----------       -----------
<S>                       <C>               <C>               <C>               <C>        
Basic EPS

  Net income              $ 1,075,000       $ 1,234,000       $ 2,295,000       $ 2,059,000
  Less accretion             (359,000)         (245,000)         (808,000)         (575,000)
                          -----------       -----------       -----------       -----------
                          $   716,000       $   989,000       $ 1,487,000       $ 1,484,000
                          ===========       ===========       ===========       ===========

Shares outstanding          5,533,959         5,717,201         5,630,489         5,718,679

Per share amounts         $      0.13       $      0.17       $      0.26       $      0.26
                          ===========       ===========       ===========       ===========

Dilutive Effect

  Net income              $ 1,075,000       $ 1,234,000       $ 2,295,000       $ 2,059,000
  Less accretion             (359,000)         (245,000)         (808,000)         (557,000)
                          -----------       -----------       -----------       -----------
                          $   716,000       $   989,000       $ 1,487,000       $ 1,502,000

Shares outstanding          5,533,959         5,664,288         5,630,489         5,718,679
Stock options                 546,784           361,557           261,431           163,412
Deferred Stock                 68,858            48,590            68,858            48,590
                          -----------       -----------       -----------       -----------
                            6,149,601         6,074,435         5,960,778         5,930,681

   Per share amounts      $      0.12       $      0.16       $      0.25       $      0.25
                          ===========       ===========       ===========       ===========
</TABLE>

Note: Earnings per share amounts presented for prior years have been restated in
      accordance with Statement of Financial Accounting Standards No. 128,
      "Earnings Per Share".
#### NORTH AMERICAN OIL COMPANY, INC., Plaintiff-Appellee, v. STAR BRITE DISTRIBUTING, INC., Defendant-Appellant.

No. 01-1347.

United States Court of Appeals, Federal Circuit.

DECIDED: June 26, 2001.

Before MICHEL, Circuit Judge.

ON MOTION

*ORDER*

Star Brite Distributing, Inc, moves to voluntarily dismiss its appeal. Star Brite states that North American Oil Company, Inc. does not oppose.

Upon Consideration thereof,

IT IS ORDERED THAT:

(1) Star Brite’s appeals is dismissed.

(2) Each side shall bear its own costs.
Before the Second Division,

July 10, 1967

No. P67/230.

#### E. Miltenberg, Inc. *v.*United States, protest 65/13862 (New York).

Rao, C. J.

In accordance with stipulation of counsel that the merchandise covered by the foregoing protest consists of parts of stethoscopes similar in all material respects to those the subject of *Empire Findings Co., Inc.*v. *United States*(51 Cust. Ct. 262, Abstract 68126), the claim of the plaintiff was sustained.
From: fernje@charter.net

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 9:01:33 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients. If you do not reverse course I ask you to expand conscience protections for

any organizations that provide individual and group insurance and have moral or religious objections. I

strongly oppose the government forcing free insurance coverage on Americans especially for drugs and

devices that I oppose because some of these can cause an abortion (such as ella and Plan B).

I also ask you to reconsider your definition of religious employer and offer an authentic conscience

protection for any organization and business that has moral or religious objection to providing such

insurance to their employees. This legal mandate clearly violates the spirit of conscience laws which

prohibit government discrimination against those who object to various health services on moral or

religious grounds. The definition of "religious employer" in the regulation is so narrow as to only include

churches, but will still mean that a host of businesses and organizations that have conscience objections

will be required to choose between either violating their conscience or not being able to offer employees

health insurance.

Please protect the conscience rights of insurers, providers and people like me who object to being

forced by the federal government to offer or subsidize contraceptives and sterilization services, especially

when some of these drugs can take the life of early unborn children. No Americans should be forced by

the federal government to essentially subsidize services they object to. I again urge you in the strongest

way possible to reverse course and remove contraceptives and sterilizations from the list of mandatory

preventive services.

Sincerely,

Fern Jessop

Greenville, MI 48838
##### 



Exhibit 31.2
 CERTIFICATION
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
  1.
    
    I have reviewed this quarterly report on Form 10-Q of SPARTA, Inc.;2.
    
    Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;3.
    
    Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;4.
    
    The registrants other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for the registrant and have:
 a)
    
    Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is
made known to us by others within those entities, particularly during the period in
which this report is being prepared;b)
    
    Evaluated the effectiveness of the registrants disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report
based on such evaluation; andc)
    
    Disclosed in this report any change in the registrants internal control over
financial reporting that occurred during the registrants most recent fiscal quarter
(the registrants fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrants
internal control over financial reporting; and
 5.
    
    The registrants other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrants auditors and the
audit committee of registrants board of directors (or persons performing the equivalent
functions):
 a)
    
    All significant deficiencies and material weaknesses in the design or operation
of internal control over financial reporting which are reasonably likely to adversely
affect the registrants ability to record, process, summarize and report financial
information; andb)
    
    Any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrants internal control over financial
reporting.
  /s/ David E. SchreimanDavid E. SchreimanChief Financial Officer(Principal Accounting Officer)
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

UNITED STATES ATTORNEY 1201 PACIFIC AVENUE, SUITE 700

TACOMA, WASHINGTON 98402 (253) 428-3800

ORDER, Continuance of Trial/U.S. v. Jordan et al, — 1

CR05-5823RBL

Judge Leighton

UNITED STATES DISTRICT COURT

WESTERN DISTRICT OF WASHINGTON

AT TACOMA

UNITED STATES OF AMERICA, )

) NO. CR05-5823RBL

Plaintiff, )

)

v. ) ORDER

)

MICHAEL JORDAN, )

THOMAS DUNIGAN, and )

MARKUS MOORE, )

)

Defendants. ) )

THIS MATTER having come before the Court upon a motion by defendant Jordan for a

continuance of the trial, and the Court being fully advised in the matter and having considered the

motion and attached affidavit of defense counsel, and having heard from all parties at the January

26, 2007, hearing concerning the arraignment of the defendants on the Fourth Superseding

Indictment and the Pretrial Conference,

THE COURT HEREBY FINDS that:

(1) a Fourth Superseding Indictment, which added a new charge of First Degree Felony

Murder as to all three defendants, was returned on January 24, 2007; and

(2) due to the need of counsel for defendant Jordan to explore issues of some complexity,

including all relevant issues and defenses applicable to the case in general and the new charge and

some new discovery in particular, it appears that defendant Jordan could not be fully prepared for

Case 3:05-cr-05823-RBL Document 183 Filed 02/01/07 Page 1 of 2
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

UNITED STATES ATTORNEY 1201 PACIFIC AVENUE, SUITE 700

TACOMA, WASHINGTON 98402 (253) 428-3800

ORDER, Continuance of Trial/U.S. v. Jordan et al, — 2

CR05-5823RBL

trial as scheduled on February 5, 2007;

IT IS HEREBY ORDERED that:

(1) the trial date is continued from February 5, 2007 to February 26, 2007;

(2) the resulting period of delay from January 26, 2007 through February 26, 2007 is

excluded for speedy trial purposes under 18 U.S.C. § 3161(h)(8)(A), because the ends of justice

served by granting this continuance outweigh the best interests of the public and the defendants in

a speedy trial;

(3) the resulting period of delay from January 26, 2007 through February 26, 2007 is also

excluded for speedy trial purposes under 18 U.S.C. § 3161(h)(8)(B), because the defense needs

time to explore issues of some complexity, including all relevant issues and defenses applicable to

the case, which would make it unreasonable to expect adequate preparation for pretrial

proceedings or for the trial itself within the time limits previously set for this case; and

(4) defendants Thomas Dunigan and Markus Moore, over their objection, are included in

this Order pursuant to 18 U.S.C. § 3161(h)(7).

IT IS SO ORDERED this 1st day of February, 2007. ARONALD B. LEIGHTON

UNITED STATES DISTRICT JUDGE

Presented by:

 s/ 

GREGORY A. GRUBER

Assistant United States Attorney

Case 3:05-cr-05823-RBL Document 183 Filed 02/01/07 Page 2 of 2
From: margie.kaminski@gmail.com

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 7:32:01 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients. If you do not reverse course I ask you to expand conscience protections for

any organizations that provide individual and group insurance and have moral or religious objections. I

strongly oppose the government forcing free insurance coverage on Americans especially for drugs and

devices that I oppose because some of these can cause an abortion (such as ella and Plan B).

I also ask you to reconsider your definition of religious employer and offer an authentic conscience

protection for any organization and business that has moral or religious objection to providing such

insurance to their employees. This legal mandate clearly violates the spirit of conscience laws which

prohibit government discrimination against those who object to various health services on moral or

religious grounds. The definition of "religious employer" in the regulation is so narrow as to only include

churches, but will still mean that a host of businesses and organizations that have conscience objections

will be required to choose between either violating their conscience or not being able to offer employees

health insurance.

Please protect the conscience rights of insurers, providers and people like me who object to being

forced by the federal government to offer or subsidize contraceptives and sterilization services, especially

when some of these drugs can take the life of early unborn children. No Americans should be forced by

the federal government to essentially subsidize services they object to. I again urge you in the strongest

way possible to reverse course and remove contraceptives and sterilizations from the list of mandatory

preventive services.

Sincerely,

Margaret Kaminski

North Olmsted, OH 44070
EXHIBIT 32.2

Certification of CFO Pursuant to

18 U.S.C.
Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection
with the Quarterly Report on Form 10-Q of Ambac Financial Group, Inc. (the Company) for the period ended September 30, 2009, as filed with the Securities and Exchange Commission on the date hereof (the Report), Sean T.
Leonard, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of
the Company.

|                                                                                                         
|---------------------------------------------------------------------------------------------------------
|                                                                                                         
|/s/    Sean T. Leonard                                                                                   
|Name: Sean T. Leonard Title:   Senior Vice President and Chief Financial Officer Date:
  November 9, 2009
Exhibit
      32.1


**CERTIFICATION
      PURSUANT TO 18 U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO SECTION 906**


**OF
      THE SARBANES-OXLEY ACT OF 2002**




This
      Certification accompanies the Form 10-QSB for the quarterly period ended March
      31, 2007 of BioSpecifics Technologies Corp.





The
      undersigned, Thomas L. Wegman, the President, Principal Executive Officer and
      Principal Financial Officer of BioSpecifics Technologies Corp. (the “Company”),
      DOES HEREBY CERTIFY that:




1.
            The
                Company’s Form 10-QSB for the quarterly period ended March 31, 2007 (the
                “Report”), fully complies with the requirements of Section 13(a) of the
                Securities Exchange Act of 1934;
                and





2.
            Information
                contained in the Report fairly presents, in all material respects,
                the
                financial condition and results of operation of the
                Company.




IN
      WITNESS WHEREOF, each of the undersigned has executed this statement this 26th
      day of September, 2007.




/s/
          Thomas L. Wegman
 
 Thomas
          L.
          Wegman
 President
 (Principal
          Executive Officer and Principal Financial Officer)










A
      signed
      original of this written statement required by Section 906 has been provided
      to
      BioSpecifics Technologies Corp. and will be retained by BioSpecifics
      Technologies Corp. and furnished to the Securities and Exchange Commission
      or
      its staff upon request.
<PAGE>

                                                                    EXHIBIT 32.2

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

                             Chief Financial Officer

The undersigned, as the chief financial officer of Allied Healthcare Products,
Inc. (the "Company") does hereby certify for purposes of 18 U.S.C. Section 1350
that (i) the Company's Quarterly Report on Form 10-Q for the Company's fiscal
quarter ending September 30, 2004 (the "Report"), as filed with the Securities
and Exchange Commission on April 30th, 2004, fully complies with the
requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934
and (ii) information contained in the periodic report fairly presents, in all
material respects, the financial condition and results of operations of the
Company as of and for the periods covered in the Report.

                                    /s/ Daniel C. Dunn
                                    -------------------------
                                        Daniel C. Dunn, Chief Financial Officer

                                        November 5, 2004